Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A syndrome characterized by total alopecia (hair loss), total vitíligo, and nail changes. The nail changes consist of fine pitting, associated with softness, and friability and may include horizontal splitting. The vitiligo is characterized by complete, rapid uniform loss of pigment which occurs without going through a patchy state. The entire cutaneous surface is light and translucent-appearing and is prone to burning on exposure to the sun.
No clinical trials have been registered for alopecia universalis onychodystrophy vitiligo.
1 publication has been identified in PubMed for alopecia universalis onychodystrophy vitiligo. Research spans Review / Meta-Analysis (100%).
Tordjman L (2025). [PMID: 39934092](https://pubmed.ncbi.nlm.nih.gov/39934092/). *Int J Dermatol*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 8:33 PM UTC
Genetic and Rare Diseases Info Center
AI-curated news mentioning alopecia universalis onychodystrophy vitiligo
Updated Mar 16, 2026
A case report highlights the development of vitiligo and alopecia universalis in a patient with myasthenia gravis after receiving rituximab therapy. This finding may prompt further investigation into the side effects of rituximab in rare disease populations.